Determinants of Paclitaxel Uptake, Accumulation and Retention in Solid Tumors
暂无分享,去创建一个
[1] S. Howell,et al. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. , 1994, British Journal of Cancer.
[2] M. Wientjes,et al. Pharmacodynamics of taxol in human head and neck tumors. , 1996, Cancer research.
[3] W. B. Derry,et al. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. , 1996, Cancer research.
[4] H. Sasano,et al. Potential of the histoculture drug-response assay to contribute to cancer patient survival. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] L. Grochow,et al. High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. , 1987, Cancer treatment reports.
[6] K. Bhalla,et al. Characterization of a human myeloid leukemia cell line highly resistant to taxol. , 1994, Leukemia.
[7] B. Sikic,et al. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). , 1996, Cancer research.
[8] M. Jordan,et al. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[9] L. Peters,et al. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol , 1995, Cancer Chemotherapy and Pharmacology.
[10] M. Bibby,et al. Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids. , 1997, European journal of cancer.
[11] B. Monsarrat,et al. Taxol: pharmacology, metabolism and clinical implications. , 1993, Cancer surveys.
[12] Earl G. Adams,et al. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines , 2004, Cancer Chemotherapy and Pharmacology.
[13] B. Baguley,et al. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, 1994: PHARMACOKINETIC/CYTOKINETIC PRINCIPLES IN THE CHEMOTHERAPY OF SOLID TUMOURS , 1995, Clinical and experimental pharmacology & physiology.
[14] R. Hoffman,et al. Sponge-gel-supported histoculture drug-response assay for head and neck cancer. Correlations with clinical response to cisplatin. , 1994, Archives of otolaryngology--head & neck surgery.
[15] K. Tew,et al. P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. , 1994, Journal of the National Cancer Institute.
[16] J Parness,et al. Taxol binds to polymerized tubulin in vitro , 1981, The Journal of cell biology.
[17] E. Reed,et al. Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer , 2004, Cancer Chemotherapy and Pharmacology.
[18] B. Sikic,et al. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Haber,et al. Altered Expression of M2, the Class II -Tubulin Isotype, in a Murine J774.2 Cell Line with a High Level of Taxol Resistance (*) , 1995, The Journal of Biological Chemistry.
[20] M. Wientjes,et al. Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. , 1998, Cancer research.
[21] J. Carlsson,et al. Relations between the penetration, binding and average concentration of cytostatic drugs in human tumour spheroids , 2004, Cancer Chemotherapy and Pharmacology.
[22] K. Cowan,et al. Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and glutathione S-transferase-pi. , 1990, Molecular pharmacology.
[23] M. Wientjes,et al. Computational model of intracellular pharmacokinetics of paclitaxel. , 2000, The Journal of pharmacology and experimental therapeutics.
[24] W D Lawrence,et al. Paclitaxel‐induced apoptosis in MCF‐7 breast‐cancer cells , 1997, International journal of cancer.
[25] D. Song,et al. Binding of taxol to plastic and glass containers and protein under in vitro conditions. , 1996, Journal of pharmaceutical sciences.
[26] V. Ling,et al. P-glycoprotein, multidrug resistance and tumor progression , 1994, Cancer and Metastasis Reviews.
[27] M. Wientjes,et al. Determinants of paclitaxel penetration and accumulation in human solid tumor. , 1999, The Journal of pharmacology and experimental therapeutics.
[28] Jörgen Carlsson,et al. Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids , 2004, Cancer Chemotherapy and Pharmacology.
[29] I. Pastan,et al. Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.
[30] J. Manfredi,et al. Taxol binds to cellular microtubules , 1982, The Journal of cell biology.
[31] R. Hoffman,et al. Clinical applications of the histoculture drug response assay. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.